Abeona Therapeutics Inc vs Amgen, Inc. — how do they compare? Abeona Therapeutics Inc trades at $7.57 (market cap $421.19M), while Amgen, Inc. trades at $412.21 (market cap $224.14B). The key difference: Amgen, Inc. is far larger — about 532.2× Abeona Therapeutics Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | AMGN | |
|---|---|---|
Market Cap | $421.19M | $224.14B |
Sector | Health | Health |
52-Week High | $7.45 | $417.20 |
52-Week Low | $4.17 | $271.18 |
Enterprise Value | $276.10M | $267.45B |
Dividend Yield | — | 2.43% |
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →